WO1998010792A1 - Therapie a but immunitaire - Google Patents

Therapie a but immunitaire Download PDF

Info

Publication number
WO1998010792A1
WO1998010792A1 PCT/IB1996/000945 IB9600945W WO9810792A1 WO 1998010792 A1 WO1998010792 A1 WO 1998010792A1 IB 9600945 W IB9600945 W IB 9600945W WO 9810792 A1 WO9810792 A1 WO 9810792A1
Authority
WO
WIPO (PCT)
Prior art keywords
glu
asp
lys
arg
immune
Prior art date
Application number
PCT/IB1996/000945
Other languages
English (en)
Inventor
Patrick T. Prendergast
Original Assignee
Prendergast Patrick T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prendergast Patrick T filed Critical Prendergast Patrick T
Priority to AU68870/96A priority Critical patent/AU6887096A/en
Publication of WO1998010792A1 publication Critical patent/WO1998010792A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the host is then capable of overcoming an infectious challenge without becoming infected or producing the usual antibody and autoantibody peak and subsequent immunosuppression normally associated with infections caused by organisms who utilise these specific amino acid sequences to direct the hosts immune signalling system towards a more pronounced B cell or Th 2 cytokine profiled response.
  • Malaria is one of the most important infectious diseases in the World, each year there are 270 million new infections resulting in over 100 million episodes of illness and approximately 2 million deaths. World-wide the malaria problem is getting worse each year.
  • the reason for this worsening situation include (A) increased levels of drug resistance on the part of the parasites, (B) increased levels of insecticide resistance on the part of the vectors .
  • No vaccine has yet been produced which can successfully induce a protective antibody response and the reason for this is that although antibodies which cross react with many epitopes of the P.
  • vivax circumsporozoite are produced in abundance by the current unprotective vaccine candidates, because of the immune blind spot or immunologically privileged sites offered by these specific sequences identified herein, like Interleukin 10 and AFP are not visible to the host immune system which both allow the parasite to gain access to the host cell and to cause the non-specific polyclonal B cell activation and immunosuppressive (Interleukin 10 and/or AFP) like effects which are so universal for people suffering from parasites such as malaria, and Leishmania, the host cannot gain enough immune reactive monocytes to overcome the infection initially because these Interleukin 10/AFP mimic molecules carried by the infecting organism shuts down the vital Th x T cell response needed to clear intra-cellular infections.
  • Interleukin 10 and AFP non-specific polyclonal B cell activation and immunosuppressive
  • a vaccine for malaria which will enable a human to raise a protective antibody titre against malaria sufficient to prevent infection may be manufactured using amino acid sequences displaying these specific polar arrays.
  • Another method expected to be more successful as a vaccine combination is to use passive immunisation with either polyclonal or monoclonal antibodies to these said specific sequences generated either in animal human and/or tissue culture given either before or simultaneously with any of the current malaria vaccine candidates which previously could not produce a protective immune response.
  • the said specific sequence when embedded in the cell membrane of the host activate the phosphatidylinositol pathway, which causes the release of Ca++, the phosphosylation of cell proteins and the activation or enhanced activity of certain enzymes related to metabolism. This does not occur in the presence of antibodies to the disclosed specific sequences and the organism like malaria, Mycobacterium Tuberculosis, Leishmania, HIV and others are not able to cause metabolic and immune Th 2 activation and exhaustion. It is an important coincidence that in certain malaria endemic areas that genetic mutations that have caused the deletion of the metabolic activity control enzyme glucose- 6 -phosphate dehydrogenase has conferred on the host immunity to malaria. By intervening at an early stage of infection and neutralising certain properties of the malaria parasite to alter cellular reactions by interfering with these specific membrane signal transduction sequences as defined herein it is possible to confer protective immunity to this organism.
  • the present invention utilises the novel discovery that certain amino acid sequences which exhibit specific Ion (bridge) pair arrays enclosed on at least one side by non-polar hydrophobic transmembrane segments can be utilised to enhance the humoral antibody response and down-regulate the T cell or delayed-type hypersensitivity (DTH) response of humans and animals.
  • Ion bridge
  • DTH delayed-type hypersensitivity
  • CD3/TCR mimic membrane interaction molecules which present as hydrophobic Ion bridge pairs are utilised by both the organism itself as specific peptides and by cytokines and also by infectious agents to modulate immune response (A) during periods of reproductive foetal gestation as with the alpha-fetoprotein molecule to prevent foetal rejection by the maternal immune system and (B) during cytokine control of immune functions as with cytokine synthesis inhibitory factor (Interleukin 10) when a Th 2 cytokine profile is required or to curtail the uncontrolled Th ⁇ T4 cell immune response.
  • cytokine This cytokine (IL-10) is particularly evident following vaccination to enhance humoral immunity and secure antibody formation, and often causes the temporary disappearance of the Tuberculin reaction which is associated with Th : (DTH) response in patients following vaccination.
  • Infectious agents such as viruses (RNA & DNA) mycoplasma, bacteria, malaria and a wide array of human and animal parasites also carry these specific charged array of amino acid sequences which cause the down regulation of the T4 cell response and enhance the humoral (antibody mediated) immune response of their infected host, see sample listing enclosed.
  • Anti-serum generated to these specific sequences as presented in AFP, Interleukin 10, EBV-BCRF1 and other peptides and as specified in amino acid sequence, listing enclosed, with this patent can be used to remove Interleukin 10 mimic molecules from the circulation of immunosuppressed patients suffering from viral and/or bacterial and/or fungal, mycoplasmic or parasitic infections, which infection's principle method of defence against the host is to stimulate a Th2 cytokine response and curtail or abolish the Thl cell mediated immune attack.
  • This invention relates to methods of treatment of persons and animals with indications of immunodeficiency, wherein the said indication is resultant from viral and/or retroviral infection and/or infectious parasites, bacteria and/or mycoplasma.
  • the invention further relates to treatment with the above antiserum either poly or monoclonal in nature for establishing improved immuno response for persons and prophylactic treatment for persons where immuno-malfunction due to genetic pre-disposition or infection is considered a future risk.
  • the invention further relates to a screening method for vaccines, manufactured by the use of coat or other peptides from viral, bacterial, parasitic or mycoplasma, to determine and remove and/or neutralise inherent immune suppressive properties - such suppressive potential properties is determined by the manufactured vaccine's reactivity with the said specific amino acid sequences as outlined herein, be they synthetic or natural in origin, e.g. AFP, Interleukin 10, viral or bacterial coat peptides.
  • the host organism man or animal
  • Treatments used according to this invention employing the poly or monoclonal antiserum to these specific cytokine inhibitory sequences are administered as treatments against viral, bacterial and mycoplasma and parasitic infections which cause immunosuppression by any suitable route including enteric, parenteral, topical, oral, rectal, nasal or vaginal routes.
  • Parenteral routes include subcutaneous, intramuscular, intravenous and sublingual administration. The preferred route of administration would be an intravenous one.
  • the present invention further provides pharmaceutical formulations, for use in treatments against HIV/HTLV- 1 , II, III and other viral diseases and diseases caused by mycoplasma, bacteria or parasites.
  • the present invention also relates to a method comprising inoculating into a patient a human, animal, synthetic or recombinant amino acid sequence with or without adjuvant, to produce an antibody response, the antibodies, mono or polyclonal will cause the binding of the immunosuppressive CD3/TCR mimic interaction molecules already present in the plasma of the infected host will be removed from the circulation of the infected host and normal immune function demonstrating a Th x cytokine profile, i.e. Interleukin 2 and gamma interferon, capable of resisting the infection will be re-established.
  • a Th x cytokine profile i.e. Interleukin 2 and gamma interferon
  • Vaccines manufactured by the use of coat or other peptides from viral, bacterial, parasitic or mycoplasma may be screened to determine whether they posses these specific amino acid sequences which exhibit these specific Ion bridge pair arrays capable of mimicking the actions of AFP or Interleukin 10 and there inherent immune suppressive properties - such suppressive potential properties is determined by the manufactured vaccine's reactivity with any of the said specific amino acid sequences listed herein which may be removed or neutralised by the antiserum specified in this patent .
  • Suitable dosages in accordance with the present invention depend on many factors, e.g. the patient's weight, the mode of administration, the frequency of administration, the type of affliction being treated or prevented, whether the infection presently exists, and if so, to what degree. Suitable dosages for given situations can readily be determined by those skilled in the art without undue experimentation.
  • the total treatment time according to the present invention will vary from patient to patient based on sound medical judgement and factors particular to the patient being treated, such as, for example, the age and physical condition of the patient. Those skilled in the art can easily determine suitable total treatment time on a patient by patient basis.
  • HIV-1 Human Immunodeficiency Virus Type 1
  • AIDS Acquired Immune Deficiency Syndrome
  • AIDS is characterised as a profound breakdown in host's cellular and humoral immunity and increased susceptibility to a wide range of opportunistic infections.
  • One of the consequences of this immune dysfunction is a marked depletion in absolute CD4+ cells in HIV- infected individuals. Studies over the past years have demonstrated that the destruction of the immune system by HIV-1 is a chronic process, starting at the moment of infection.
  • the major histocompatibility complex is a collection of 40-50 genes arrayed within a long continuous stretch of DNA on chromosome 6 in humans .
  • the MHC is referred to as the HLA complex in humans.
  • the MHC genes are organised into regions encoding three classes of molecules: Class I, Class II and Class III.
  • the Class I genes encode glycoproteins expressed on the surface of nearly all nucleated cells, where they present peptide antigens of altered self-cells necessary for the activation of T c cells.
  • the Class II genes encode glycoproteins expressed primarily on antigen-presenting cells (macrophages, dendritic cells, and B cells), where they present processed antigenic peptides to Th cells.
  • the Class III genes encode somewhat different products that are also associated with the immune process. These include a number of soluble serum proteins (including components of the complement system) , steroid 21-hydroxylase enzymes, and tumour necrosis factors.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • a number of white blood cells have cytotoxic potential and express membrane receptors for the Fc region of the antibody IgG molecule.
  • this antibody is specifically bound to a target cell which occurs when these specific poly or monoclonal antibodies to these sequences present on AFP, Interleukin 10 bind to HIV infected cells or free viral peptides causing immune Th2 shift.
  • Interleukin 10 bind to HIV infected cells or free viral peptides causing immune Th2 shift.
  • These cytotoxic Fc receptor-bearing cells can bind to the antibodies' Fc region, and thus to the infected HIV cells, and subsequently cause lysis of these cells.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • the variety of cells that have been shown to exhibit ADCC include NK cells. Macrophages, monocytes, neutrophils, and eosinophils. 2.0 OBJECTIVES 2.1 To provide for an administration of monoclonal antibodies to these specified sequences present on AFP and Interleukin 10 and other cytokines and infectious organisms to HIV+ patients. 2.2 To monitor immune system functioning before and after the administration of these mono or polyclonal antibodies.
  • Beta-2-microglobulin level 3.6. Appearance of new or improvement of active opportunistic infections.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

L'invention concerne une séquence d'acides aminés présentant des groupes de paires d'ions spécifiques (ponts) ceints au moins d'un côté par des segments transmembranaires hydrophobes non polaires, en tant que mécanisme utilisé par de nombreux agents infectieux et plusieurs facteurs d'inhibition de la cytokine, tels que l'interleukine 10, le facteur d'inhibition de la prolactine et l'alpha-foeto-protéine. Ladite séquence n'est pas seulement utilisée pour amoindrir les défenses immunitaires des hôtes mais également pour permettre l'infection de tissus lymphoïdes cibles. Il a été prouvé que certains vaccins, lorsqu'ils sont inoculés à un hôte, produisent un certaine gamme d'anticorps neutralisants mais n'empêchent pas l'infection lorsque l'hôte est ensuite exposé à un organisme infectieux vivant. Dans la thérapie de l'invention, lorsque l'inoculation de ce type de vaccin est combinée à une immunisation passive au moyen d'anticorps mono ou polyclonaux dirigés contre lesdites séquences d'acides aminés, l'hôte est capable de surmonter l'agression infectieuse. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre lesdites séquences spécifiques pour le traitement du syndrome d'immunodéficience acquise (SIDA) et d'autres états pathologiques qui persistent en raison de la présence d'un facteur d'inhibition de la cytokine d'origine virale, bactérienne ou provenant de l'hôte, tel que le syndrome de fatigue chronique dans lequel les molécules d'imitation de l'interleukine 10 sont responsables d'une multitudes de symptômes identifiés comme indicateurs de l'encéphalomyélite. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre ces séquences d'acides aminés spécifiques, sous forme de thérapie associée au moyen de vaccins et d'agents antiviraux pour la prévention des effets secondaires de certains agents de modulation des défenses immunitaires et antiviraux (ex: DHEA et IL-12) qui provoquent la production accrue de molécules d'imitation de l'interleukine 10 ou de l'alpha-foetoprotéine pendant la thérapie. L'invention se rapporte encore à l'utilisation thérapeutique de ces séquences spécifiques soit isolées de la source de l'organisme source ou produits par synthèse directe ou synthèse de protéines recombinaison. Ces peptides, lorsqu'ils sont administrés à un patient souffrant d'une maladie auto-immune, tels que, entre autres, la sclérose en plaques, le lupus érythémateux (lupus érythémateux systémique), le diabète ou la polyarthrite rhumatoïde ou à des receveurs de transplant, permettent de modifier l'état immunitaire du patient de sorte que soit produite 'une réponse immunitaire dépendante de l'anticorps Th2 et que soit inhibée l'attaque immunitaire de Th1 (dépendant des lymphocytes) qui se manifeste dans ces types de déficiences immunitaires, telles que la sclérose en plaques et la réaction du greffon contre l'hôte. Certaines affections dermatologiques qui sont aujourd'hui traitées au moyen de crèmes et d'onguents corticostéroïdes peuvent être également traitées avec succès par le remplacement des corticostéroïdes par ces séquences immunosuppressives d'imitation de l'interleukine 10 et de l'alpha-foetoprotéine de l'invention.
PCT/IB1996/000945 1996-09-11 1996-09-13 Therapie a but immunitaire WO1998010792A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68870/96A AU6887096A (en) 1996-09-11 1996-09-13 Immune direction therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2518096P 1996-09-11 1996-09-11
US60/025,180 1996-09-11

Publications (1)

Publication Number Publication Date
WO1998010792A1 true WO1998010792A1 (fr) 1998-03-19

Family

ID=21824510

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1996/000945 WO1998010792A1 (fr) 1996-09-11 1996-09-13 Therapie a but immunitaire
PCT/IB1997/001086 WO1998010787A2 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/001086 WO1998010787A2 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire

Country Status (9)

Country Link
EP (1) EP0929568A2 (fr)
JP (1) JP2001503613A (fr)
CN (1) CN1230195A (fr)
AU (2) AU6887096A (fr)
CA (1) CA2265885A1 (fr)
IL (1) IL128806A0 (fr)
NZ (1) NZ335039A (fr)
SE (1) SE9900812L (fr)
WO (2) WO1998010792A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
US7589184B2 (en) 2004-05-24 2009-09-15 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US7989590B2 (en) * 2005-03-22 2011-08-02 Rohto Pharmaceutical Co., Ltd Peptides that increase collagen or hyaluronic acid production
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
EP2989120A4 (fr) * 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Peptides anti-inflammatoires synthétiques et leur utilisation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5297299A (en) * 1998-08-17 2000-03-06 Patrick T. Prendergast Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
WO2000035472A2 (fr) * 1998-12-15 2000-06-22 Hollis-Eden Pharmaceuticals, Inc. Cytokinotherapie combinee
EP1265634A4 (fr) * 2000-03-14 2005-12-28 Nat Jewish Med & Res Center Procede et composition pour traiter une hyperreactivite bronchique
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
EA008925B1 (ru) * 2004-12-14 2007-08-31 Товарищество С Ограниченной Ответственностью "Реал Мед Компани" Способ коррекции иммунного состояния организма при сахарном диабете
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN114163493B (zh) * 2021-11-18 2023-09-15 浙大宁波理工学院 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017698A1 (fr) * 1992-03-04 1993-09-16 Schering Corporation Utilisation d'interleukine-10 pour supprimer des maladies provoquees par la reaction du greffon contre l'hote
WO1993018783A1 (fr) * 1992-03-20 1993-09-30 Schering Corporation Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1
WO1994006473A1 (fr) * 1992-09-18 1994-03-31 Schering Corporation Retablissement de l'immunosuffisance des lymphocytes t auxiliaires chez des patients contamines par le vih

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056249B1 (fr) * 1981-01-09 1985-06-26 New York Blood Center, Inc. Composition synthétique d'antigènes et leur procédé de préparation
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
AU1366088A (en) * 1987-01-28 1988-08-24 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
AU620804B2 (en) * 1987-03-23 1992-02-27 Hiver Limited Novel vaccines
SE8705197D0 (sv) * 1987-12-30 1987-12-30 Jonas Blomberg New peptides, two diagnostic methods using the peptides and a medicament based on the peptides
IL97629A0 (en) * 1990-03-26 1992-06-21 Schering Corp Bcrf1 antagonists for treating epstein-barr virus infections
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
NZ269766A (en) * 1993-07-28 1998-01-26 Medvet Science Pty Ltd Haemopoietic growth factor antagonists; relates to modified forms of such factors
DE69536065D1 (de) * 1994-01-14 2010-05-27 Rath Matthias Hydrophile Signal-Oligopeptide und Verfahren der therapeutischen Anwendung
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017698A1 (fr) * 1992-03-04 1993-09-16 Schering Corporation Utilisation d'interleukine-10 pour supprimer des maladies provoquees par la reaction du greffon contre l'hote
WO1993018783A1 (fr) * 1992-03-20 1993-09-30 Schering Corporation Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1
WO1994006473A1 (fr) * 1992-09-18 1994-03-31 Schering Corporation Retablissement de l'immunosuffisance des lymphocytes t auxiliaires chez des patients contamines par le vih

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. LANDAY ET AL.: "In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: Effects of interleukin (IL)-12 and anti-IL-10.", THE JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 5, May 1996 (1996-05-01), CHICAGO, IL, USA, pages 1085 - 1091, XP000674644 *
L. BROWN ET AL.: "Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.", ARCHIVES OF VIROLOGY, vol. 140, no. 4, 1995, VIENNA, AUSTRIA, pages 635 - 654, XP000674654 *
M. CLERICI ET AL.: "Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 2, February 1994 (1994-02-01), NEW YORK, NY, USA, pages 768 - 775, XP000674643 *
S. VANINI ET AL.: "Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies.", AIDS, vol. 7, no. 2, February 1993 (1993-02-01), LONDON, GB, pages 167 - 174, XP000674642 *
T. MCCUTCHAN ET AL.: "Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax.", SCIENCE, vol. 230, no. 4732, 20 December 1985 (1985-12-20), WASHINGTON, DC, USA, pages 1381 - 1383, XP000674496 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589184B2 (en) 2004-05-24 2009-09-15 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US7989590B2 (en) * 2005-03-22 2011-08-02 Rohto Pharmaceutical Co., Ltd Peptides that increase collagen or hyaluronic acid production
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US8951719B2 (en) 2008-09-12 2015-02-10 Gentegra, LLC. Matrices and media for storage and stabilization of biomolecules
US9637513B2 (en) 2008-09-12 2017-05-02 Gentegra Llc Matrices and media for storage and stabilization of biomolecules
US10160997B2 (en) 2008-09-12 2018-12-25 Gentegra Llc Matrices and media for storage and stabilization of biomolecules
EP2989120A4 (fr) * 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Peptides anti-inflammatoires synthétiques et leur utilisation
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof

Also Published As

Publication number Publication date
EP0929568A2 (fr) 1999-07-21
AU4132097A (en) 1998-04-02
NZ335039A (en) 2001-04-27
SE9900812D0 (sv) 1999-03-08
WO1998010787A3 (fr) 1998-07-30
CN1230195A (zh) 1999-09-29
JP2001503613A (ja) 2001-03-21
AU6887096A (en) 1998-04-02
IL128806A0 (en) 2000-01-31
WO1998010787A2 (fr) 1998-03-19
SE9900812L (sv) 1999-03-08
CA2265885A1 (fr) 1998-03-19

Similar Documents

Publication Publication Date Title
KR100235849B1 (ko) HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
US7744896B1 (en) HIV-1 Tat compositions
Iborra et al. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice
WO1998010792A1 (fr) Therapie a but immunitaire
JP2020513782A (ja) Ｈｉｖ感染を治療するキメラ抗原受容体の組換え遺伝子構築およびその応用
Schooley et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1—infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214
AU687271B2 (en) Targeted T lymphocytes
US20110142911A1 (en) HIV epitopes and pharmaceutical composition containing same
JPH10503473A (ja) 細胞傷害性ｔリンパ球刺激およびｈｃｖ曝露診断用ｃ型肝炎ウイルスコアペプチド
Tartz et al. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria
Perdiguero et al. Heterologous combination of VSV-GP and NYVAC vectors expressing HIV-1 trimeric gp145 Env as vaccination strategy to induce balanced B and T cell immune responses
MX2010012587A (es) Vector de expresion que codifica el virus alfa replicasa y uso del mismo como adyuvante inmunologico.
AU660422B2 (en) Pathogen-specific CTL therapy
EP1545602B1 (fr) Compositions pharmaceutiques renfermant une proteine d'enveloppe du vih et cd4
US7521426B2 (en) HIV-specific CTL inducing peptides and medicaments for preventing or treating AIDS comprising the peptides
Lee et al. A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120
Bretscher An hypothesis to explain why cell‐mediated immunity alone can contain infections by certain intracellular parasites and how immune class regulation of the response against such parasites can be subverted
Barnes Strategies for an AIDS Vaccine: In their attempts to develop a vaccine against AIDS, many scientists focus on raising antibodies to a protein from the AIDS virus, a strategy that some researchers think may require modification
WO2016080392A1 (fr) Vaccin et vaccin prime-boost (amorce-rappel)
WO2012040266A2 (fr) Adjuvants de type gène et compositions les contenant pour augmenter la production d'anticorps en réponse à des vaccins géniques
Calarota et al. Cellular HIV-1 immune responses in natural infection and after genetic immunization
Purner et al. Cross-reactivity of human Toxoplasma-specific T cells: implications for development of a potential immunotherapeutic or vaccine
KR102297440B1 (ko) 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
JP2006188513A (ja) Ｃｄ８＋細胞傷害性ｔリンパ球エピトープペプチド及びその用途
WO2020071869A1 (fr) Anticorps chimère ayant une fonction multi-immunitaire améliorée par liaison spécifique à une cellule cible, et utilisation associée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BR CA CH CN DE DK ES GB IL JP KE LU MX NO NZ PT RU SE SG US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513416

Format of ref document f/p: F